Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Gastric Cancer

Gastric Cancer

22 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Gastric Cancer

193 trials tracked for Gastric Cancer: 32 in phase 3 or 4 and 19 with published results. The most-cited published study has 1184 citations.

193Trials tracked
32Phase 3 & 4
0Recruiting
19With published results
Phase distribution
Phase 4 2 Phase 3 30 Phase 2 121 Phase 1 16 Other / NA 24
  1. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed · 1,184 cited
  2. Phase 3 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Completed · 639 cited
  3. Phase 3 Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer Completed · 521 cited
  4. Phase 3 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed · 504 cited
  5. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Completed · 480 cited
  6. Phase 3 Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer Completed · 356 cited
Show 44 more trials
  1. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Completed · 352 cited
  2. Phase 3 Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Completed · 291 cited
  3. Phase 3 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Completed · 284 cited
  4. Phase 3 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Completed · 225 cited
  5. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 220 cited
  6. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 130 cited
  7. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
  8. Phase 3 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Completed · 99 cited
  9. Phase 3 Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer Completed · 77 cited
  10. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study Completed · 55 cited
  11. Phase 3 Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient Completed · 8 cited
  12. Phase 3 Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Completed · 8 cited
  13. Phase 3 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed · 3 cited
  14. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  15. Phase 3 Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Completed
  16. Phase 3 A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer Completed
  17. Phase 3 A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Completed
  18. Phase 3 A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer Completed
  19. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension Completed
  20. Phase 3 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed
  21. Phase 3 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Completed
  22. Phase 3 A Safety and Efficacy Study in Patients With Gastric Cancer Completed
  23. Phase 3 ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer Completed
  24. Phase 3 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed
  25. Phase 3 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial Completed
  26. Phase 3 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Completed
  27. Phase 2 Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours Completed
  28. Phase 2 Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients Completed
  29. Phase 2 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer Completed
  30. Phase 2 Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Completed
  31. Phase 2 RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment Completed
  32. Phase 2 Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT) Completed
  33. Phase 2 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer Completed
  34. Phase 2 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Completed
  35. Phase 2 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer Completed
  36. Phase 2 Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer Completed
  37. Phase 2 A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. Completed
  38. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  39. Phase 2 IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer Completed
  40. Phase 2 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Completed
  41. Phase 2 Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Completed
  42. Phase 2 A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  43. Phase 2 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma Completed
  44. Phase 2 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed

Showing the 50 most-cited and recently-updated of 193 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Gastric Cancer: what the trials found

Several immunotherapies demonstrated significant improvements in survival outcomes for patients with gastric cancer. Pembrolizumab showed statistically significant improvements in Overall Survival (OS) across multiple trials, including those involving specific biomarkers like PD-L1 CPS ≥ 10 [6, 19] and in combination with chemotherapy 11. Specifically, Pembrolizumab demonstrated a median OS of 15.7 months vs 11.8 months in patients with PD-1 CPS ≥ 10 6, and 12.0 months vs 5.3 months in the same cohort 19. In trials involving Nivolumab plus chemotherapy, significant improvements were noted in both OS (14.39 vs 11.10; p<0.0001) and Progression Free Survival (PFS) (7.69 vs 6.05; p<0.0001) for patients with PD-L1 CPS ≥ 5 15. Tislelizumab also showed significant improvements in OS for both PD-L1 positive participants 21 and the overall intent-to-treat population 21.

Other targeted and systemic therapies showed varying results. TAS-102 demonstrated a statistically significant improvement in Overall Survival (5.7 vs 3.6; p=0.0003) 7, while TAS-118 plus Oxaliplatin significantly improved OS, PFS, and Time to Treatment Failure compared to standard treatments 18. In contrast, Avelumab did not show statistically significant improvements in OS [8, 14] or other primary endpoints like ORR 8. Docetaxel (XRP6976) showed a statistically significant improvement in the percentage of participants with 3-year Progression-Free Survival (PFS) 10, while Ramucirumab demonstrated an Objective Response Rate (ORR) of 41.1% vs 36.4% 13.

Clinical outcomes for other interventions were less definitive or did not reach statistical significance in primary endpoints. Olaparib did not show a statistically significant difference in OS 12 or PFS 12, and the results for Objective Response were also not statistically significant 12. 5-Fluorouracil showed a non-significant trend in Overall Survival (p=0.0565) 9. Early palliative care did not result in a statistically significant change in Quality of Life scores at 12 or 24 weeks 16.

Recent results — preliminary, needs further review

  • Perioperative treatment is being evaluated in Phase 2 trials 1.
  • Trastuzumab BS is being evaluated in a Phase N/A trial 2.

For the clinician treating this condition

  • Pembrolizumab and Tislelizumab have demonstrated statistically significant improvements in Overall Survival across multiple studies, with Pembrolizumab showing particularly strong results in patients with high PD-L1 expression.
  • TAS-102 and the combination of TAS-118 plus Oxaliplatin showed statistically significant improvements in survival metrics (OS/PFS), whereas Avelumab did not show statistically significant improvements in OS.
  • Docetaxel (XRP6976) showed a statistically significant improvement in 3-year Progression-Free Survival, while other agents like Olaparib and 5-Fluorouracil did not reach statistical significance for primary survival outcomes.

AI synthesis of 15 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis suggests immune checkpoint inhibitor regimens improve survival in advanced gastric cancer compared to chemotherapy alone
Oncology Meta-analysis
Network meta-analysis suggests immune checkpoint inhibitor regimens improve survival in advanced gastric cancer compared to chemotherapy alone New analysis suggests dual-target immune checkpoint inhibitors may improve survival for advanced gastric cancer patients
This network meta-analysis evaluated immune checkpoint inhibitor regimens versus chemotherapy for patients with advanced gastric cancer. The…
A large network meta-analysis suggests dual-target immune checkpoint inhibitors combined with chemotherapy may improve survival for advanced…
May 24, 2026
Review outlines immunotherapy roadmap for gastric cancer patients with noted limitations
Allergy & Immunology Sys. Review
Review outlines immunotherapy roadmap for gastric cancer patients with noted limitations New Immunotherapy Strategies May Help More Gastric Cancer Patients
This review examines immunotherapy options for patients with gastric cancer. The authors discuss various modalities including immune-checkpo…
New immunotherapy strategies could help more gastric cancer patients by turning cold tumors hot and personalizing treatment.
Frontiers May 12, 2026
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
Oncology Meta-analysis
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
May 1, 2026
Review of combination strategies for digestive system tumors including gastric and colorectal cancer
Allergy & Immunology Sys. Review
Review of combination strategies for digestive system tumors including gastric and colorectal cancer Unlocking New Ways to Beat Drug Resistance in Digestive Cancers
This review examines theoretical approaches to enhance efficacy in patients with digestive system tumors, including gastric, colorectal, and…
Researchers are finding better ways to combine treatments so drugs keep working longer.
Frontiers Apr 23, 2026
Digital Nutritional Care Reduces Malnutrition and Weight Loss in Post-Gastrectomy Gastric Cancer Patients
Oncology Cohort
Digital Nutritional Care Reduces Malnutrition and Weight Loss in Post-Gastrectomy Gastric Cancer Patients Digital nutrition care helped patients recover faster after stomach cancer surgery
This retrospective controlled study of 150 patients after radical gastrectomy compared a structured digital nutritional care model against r…
A digital nutrition program helped patients recover faster after stomach cancer surgery, improving weight and malnutrition rates compared to…
Frontiers Apr 23, 2026
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression
Oncology Phase II
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression New Drug Combo Gives Hope for Late-Stage Stomach Cancer
This phase II, single-center, open-label trial evaluated envafolimab combined with lenvatinib and albumin-bound paclitaxel in 30 patients wi…
Imagine a patient who has already tried every standard treatment available.
Apr 21, 2026
Probiotics shorten hospital stay and improve gut recovery after open gastrectomy for gastric cancer
Gastroenterology RCT
Probiotics shorten hospital stay and improve gut recovery after open gastrectomy for gastric cancer Probiotics may shorten hospital stay after gastric cancer surgery in small trial
In a single-centre randomized controlled trial of 42 patients undergoing open gastrectomy for gastric cancer, 10 days of postoperative probi…
Taking probiotics after open gastric cancer surgery may help patients leave the hospital sooner and recover their gut function faster.
Apr 19, 2026
Extensive intraoperative peritoneal lavage after gastrectomy for gastric cancer with peritoneal cytology positivity
Oncology Phase II
Extensive intraoperative peritoneal lavage after gastrectomy for gastric cancer with peritoneal cytology positivity Can washing the belly during surgery help prevent stomach cancer from coming back?
This single-arm exploratory phase 2 trial in 13 patients with gastric cancer and positive peritoneal cytology evaluated extensive intraopera…
A thorough belly wash during stomach cancer surgery kept patients free from recurrence for 14.5 months if their fluid tests showed no cancer…
Apr 19, 2026
Electroacupuncture at ST36, ST37, and PC6 may shorten recovery times after laparoscopic gastrectomy for gastric cancer
Gastroenterology RCT
Electroacupuncture at ST36, ST37, and PC6 may shorten recovery times after laparoscopic gastrectomy for gastric cancer Electroacupuncture may speed recovery after gastric cancer surgery in a small study
In this randomized controlled trial of 60 patients who underwent laparoscopic radical gastrectomy for gastric cancer, electroacupuncture at …
Electroacupuncture helped gastric cancer surgery patients pass gas, move their bowels, and walk sooner while reducing pain after waking from…
Apr 17, 2026
Splenectomy versus spleen preservation during total gastrectomy for gastric cancer in adults
Oncology Sys. Review
Splenectomy versus spleen preservation during total gastrectomy for gastric cancer in adults Should your surgeon remove your spleen during stomach cancer surgery?
This systematic review of randomized controlled trials evaluated adults undergoing total gastrectomy for gastric cancer in Asia and South Am…
Removing the spleen during stomach cancer surgery may be unnecessary and increases infection risks, challenging a long-standing practice.
Cochrane Apr 12, 2026

Questions about Gastric Cancer

Does CIK/DC-CIK cell therapy improve survival rates for gastric cancer?

Yes, CIK/DC-CIK cell therapy plus chemotherapy improves overall survival and disease-free survival in gastric cancer patients compared to chemotherapy alone.

Full answer →
Does EGCG have therapeutic effects on digestive system diseases like gastric cancer?

Yes, EGCG shows therapeutic effects against gastric cancer in lab and animal studies by inhibiting cell growth, inducing apoptosis, and altering immune signals, but human trials are lacking.

Full answer →
Can machine learning predict anastomotic leaks in gastric cancer patients?

Yes, machine learning models can predict anastomotic leaks in gastric cancer patients with good accuracy, especially when using postoperative indicators and immunonutritional indices.

Full answer →
Does enteral immunonutrition reduce infection risks after gastric cancer surgery?

Yes, enteral immunonutrition (EIN) reduces infection risks after gastric cancer surgery, with a 52% lower odds of infectious complications compared to standard enteral nutrition, especially when given for 7–10 days perioperatively.

Full answer →